218. アルポート症候群 Alport syndrome Clinical trials / Disease details


臨床試験数 : 26 薬物数 : 33 - (DrugBank : 13) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 29

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04937907
(ClinicalTrials.gov)
September 8, 202117/6/2021Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)Alport Syndrome, X-LinkedDrug: Hydroxychloroquine Sulfate 100 milligram (mg) Tab;Drug: Benazepril hydrochloride 10 milligram (mg) TabShanghai Children's HospitalNULLRecruiting3 Years18 YearsAll50Phase 2China
2ChiCTR2000036799
2020-10-012020-08-25Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndromeConstruction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome Alport Syndromeexperimental group:Hydroxychloroquine + Benazepril Hydrochloridec;control group:placebo + benazepril hydrochloride;Shanghai Children's HospitalNULLPending018Bothexperimental group:25;control group:25;N/AChina
3NCT00309257
(ClinicalTrials.gov)
January 200430/3/2006Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport SyndromeEffects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport SyndromeAlport SyndromeDrug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and FluvastatinMario Negri Institute for Pharmacological ResearchNULLCompleted15 Years70 YearsBoth9Phase 2Italy